Over the past 35 years following the groundbreaking proposition that tryptophan catabolism by IDO1 acts as a mechanism of T cell suppression involved in protecting the developing fetus from rejection by the maternal immune system (14), numerous studies have been directed towards elucidating the underlying basis for this immune regulatory effect and how it might be relevant to the realm of cancer therapy (50). Here, IDO1 is linked to cancer.